Vivos Therapeutics, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Vivos Therapeutics, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Cash Cushion Ratio: Debt, after subtracting cash, is 2.6 times its market value (net debt). Lower than 98% of Healthcare companies in United States.
- Shareholder Slice Ratio: Share count rose 909% in 3 years, so each share's slice of the company became smaller. Bigger rise in share count than 90% of Healthcare companies in United States.
- Growth Efficiency Ratio: Sales grew 9% in 3 years; of every extra $100 of sales, $184 became extra profit. Higher than 87% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-10.7×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 52% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
2/3 · 2/3Sales grew in 2 of the last 3 years; profit grew in 2 of 3.
Steadier than 69% of Healthcare companies in United States.
Growth Efficiency Ratio
$184Sales grew 9% in 3 years; of every extra $100 of sales, $184 became extra profit.
Higher than 87% of Healthcare companies in United States.
Asset Productivity Ratio
+9% / +83%In 3 years sales changed by +9% while total assets changed by +83%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
-1.8×Operating cash was negative last year, while some debt falls due within a year.
Higher than 64% of Healthcare companies in United States.
Cash Cushion Ratio
2.6× debtDebt, after subtracting cash, is 2.6 times its market value (net debt).
Lower than 98% of Healthcare companies in United States.
Tangible Assets Ratio
50%Of every $100 the company owns, $50 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
Less tangible than 80% of Healthcare companies in United States.
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (11)
Vivos Therapeutics, Inc. made a loss over the last year. Vivos Therapeutics, Inc. owes $1.17 for every $1 it owns. Vivos Therapeutics, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossVivos Therapeutics, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
-1.17Vivos Therapeutics, Inc.'s book value is negative (it owes more than it owns), so P/B is not meaningful.
Market cap
$4 MThe total market value of all of Vivos Therapeutics, Inc.'s shares at today's price (share price × number of shares), smaller than 94% of Healthcare companies in United States. PosiCap size class: Nano Cap.
Net worth (book value)
NegativeVivos Therapeutics, Inc.'s net worth is negative ($4 M below zero, balance sheet 30 Jun 2026): it owes more than it owns, so book value per share and P/B are not meaningful.
Return on equity (ROE)
-8585.3%Vivos Therapeutics, Inc. lost 8585.3% of its shareholders' money over the last year, lower than almost all Healthcare companies in United States.
Owes vs Owns
1.17×Vivos Therapeutics, Inc. owes $1.17 for every $1 it owns, so it owes more than it owns, higher than 91% of Healthcare companies in United States.
Dividend yield
NoneVivos Therapeutics, Inc. does not currently pay a dividend.
Revenue growth
+16%Revenue rose 16% in the year to Dec 2025, and grew 3% a year on average over 3 years.
Profit growth
LossVivos Therapeutics, Inc. made a loss in each of the last two years.
Profit margin
-121.7%Vivos Therapeutics, Inc. lost $122 for every $100 of revenue.
Cash vs debt
Net debtVivos Therapeutics, Inc. had $11 M more debt than cash (net debt) at Dec 2025.
Questions
What is Vivos Therapeutics, Inc.'s return on equity?
Vivos Therapeutics, Inc. lost 8585.3% of its shareholders' money over the last year, lower than almost all Healthcare companies in United States.
How much does Vivos Therapeutics, Inc. owe compared with what it owns?
Vivos Therapeutics, Inc. owes $1.17 for every $1 it owns, so it owes more than it owns, higher than 91% of Healthcare companies in United States.
Does Vivos Therapeutics, Inc. pay a dividend?
No. Vivos Therapeutics, Inc. does not currently pay a dividend.
Is Vivos Therapeutics, Inc.'s revenue growing?
Revenue rose 16% in the year to Dec 2025, and grew 3% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.